DocMorris Valuation

Q: What is the Fair Price of ZRSE.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

ZRSE.F ($39.03) is trading below our estimate of [[fair value]] ($347.68)

Is ZRSE.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ZRSE.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ZRSE.F ($39.03) is trading below our estimate of fair value ($347.68)

Significantly Below Fair Value: ZRSE.F is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ZRSE.F?

Key metric: As ZRSE.F is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ZRSE.F. This is calculated by dividing ZRSE.F's market cap by their current revenue.
What is ZRSE.F's PS Ratio?
PS Ratio	0.4x
Sales	CHF 1.00b
Market Cap	CHF 380.97m

ZRSE.F key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.6x
Enterprise Value/EBITDA	-10x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does ZRSE.F's PS Ratio compare to its peers?

The above table shows the PS ratio for ZRSE.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	0.4x
GRDN Guardian Pharmacy Services	1.2x	6.6%	US$1.5b
YI 111	0.03x	10.2%	US$52.4m
WBA Walgreens Boots Alliance	0.05x	1.5%	US$7.5b
CJJD China Jo-Jo Drugstores	0.08x	n/a	US$12.4m
ZRSE.F DocMorris	0.4x	16.3%	US$381.0m

Price-To-Sales vs Peers: ZRSE.F is expensive based on its Price-To-Sales Ratio (0.4x) compared to the peer average (0.4x).

Price to Sales Ratio vs Industry

How does ZRSE.F's PS Ratio compare vs other companies in the US Consumer Retailing Industry?

11 Companies	Price / Sales	Estimated Growth	Market Cap
WBA Walgreens Boots Alliance	0.05x	1.5%	US$7.49b
UNFI United Natural Foods	0.05x	0.1%	US$1.41b
SPTN SpartanNash	0.07x	1.4%	US$633.24m
YI 111	0.03x	10.2%	US$52.38m

11 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: ZRSE.F is good value based on its Price-To-Sales Ratio (0.4x) compared to the US Consumer Retailing industry average (0.4x).

Price to Sales Ratio vs Fair Ratio

What is ZRSE.F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ZRSE.F PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.4x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate ZRSE.F's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ZRSE.F forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	n/a	US$59.03 0%	33.6%	US$101.51	US$28.20	n/a	12
Nov ’25	US$38.64	US$60.60 +56.9%	33.3%	US$103.89	US$28.86	n/a	12
Oct ’25	n/a	US$77.90 0%	40.0%	US$147.72	US$31.91	n/a	12
Sep ’25	n/a	US$92.03 0%	35.5%	US$147.48	US$31.86	n/a	12
Aug ’25	US$52.99	US$100.17 +89.0%	28.2%	US$141.49	US$32.82	n/a	12
Jul ’25	n/a	US$111.51 0%	26.3%	US$147.05	US$32.80	n/a	12
Jun ’25	n/a	US$108.76 0%	25.5%	US$142.47	US$34.96	n/a	12
May ’25	US$90.00	US$108.76 +20.8%	25.5%	US$142.47	US$34.96	n/a	12
Apr ’25	US$99.00	US$98.34 -0.7%	26.5%	US$127.19	US$32.07	n/a	11
Mar ’25	n/a	US$91.42 0%	28.8%	US$123.19	US$34.02	n/a	12
Feb ’25	n/a	US$91.42 0%	28.8%	US$123.19	US$34.02	n/a	12
Jan ’25	n/a	US$79.88 0%	31.9%	US$118.08	US$33.57	n/a	12
Dec ’24	n/a	US$70.47 0%	31.4%	US$107.50	US$32.82	n/a	11
Nov ’24	n/a	US$68.46 0%	31.4%	US$104.44	US$31.88	US$38.64	11
Oct ’24	n/a	US$72.27 0%	30.1%	US$105.84	US$32.87	n/a	11
Sep ’24	US$71.36	US$70.59 -1.1%	32.8%	US$107.51	US$33.38	n/a	12
Aug ’24	n/a	US$60.39 0%	27.0%	US$92.02	US$31.06	US$52.99	12
Jul ’24	n/a	US$57.15 0%	27.5%	US$89.21	US$30.11	n/a	12
Jun ’24	US$33.25	US$58.85 +77.0%	23.4%	US$88.69	US$41.02	n/a	12
May ’24	n/a	US$59.97 0%	23.1%	US$89.48	US$34.68	US$90.00	13
Apr ’24	n/a	US$59.75 0%	22.7%	US$87.52	US$33.92	US$99.00	13
Mar ’24	n/a	US$58.96 0%	19.3%	US$77.04	US$33.64	n/a	12
Feb ’24	n/a	US$41.15 0%	61.4%	US$114.92	US$20.60	n/a	12
Jan ’24	n/a	US$58.21 0%	97.9%	US$226.53	US$20.50	n/a	12
Dec ’23	n/a	US$57.24 0%	97.7%	US$222.43	US$20.12	n/a	12
Nov ’23	n/a	US$54.88 0%	95.2%	US$209.72	US$18.97	n/a	12

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.